Articles In Press                   Back to the articles list | Back to browse issues page

XML Persian Abstract Print

1- ,
Abstract:   (2687 Views)
Cancer is one of the leading causes of death among the elderly in the world. There are various factors that contribute to the development and progression of cancer. Therefore, understanding these factors and their impact on cancer process can help in timely treatment of the disease. The purpose of this study was to investigate the factors of age of admission time and Gleason score on changing status of elderly patients with prostate cancer in Imam Khomeini Hospital in Tehran.
materials and methods:
The method of this study is a historical cohort. The data were from 125 prostate cancer patients who referred to Imam Khomeini Hospital from 2004 to 2018, and were diagnosed as a physician, underwent radical prostatectomy. After surgery, they were treated in positions Different (Radiation Therapy, Hormone Therapy, and Death). Factors influencing age of acceptance time and Gleason score on transition between states were tested using multi-state model, with R.5.0 software.
Cancer patients are considered to have an average age of 72/12 (SD = 7.32) years. According to the obtained values, the median of the patients who performed the surgery and were treated, 4.5 years in localized relapse status, 2 years in a distant recurrence and 6.6 years in detention status As. Regarding the possibility of transfusion, the patients undergoing surgery with 17% chance of being metastatic and receiving treatment for hormone replacement therapy, with a probability of 8.8%, received topical relapse and accepted radiotherapy treatment. And also with probability of% 8 death events. The results of this study showed that the Gleason variables were not significantly altered in the state of change, but the age variable in the transmission of surgical status to the state of hormone therapy was significant.

According to the results, it was found that Gleason score did not affect the transition between the considered conditions and age was significant only in the transition from surgery to hormone therapy. Therefore, in elderly patients undergoing surgery, the risk of metastasis increases with age.

Elder, Prostate Cancer, Multi-state Model
Full-Text [PDF 425 kb]   (561 Downloads)    
Type of Study: Applicable | Subject: gerontology
Received: 2019/07/09 | Accepted: 2019/12/08 | Published: 2018/12/31

1. 1Sahaf R, Khankeh HR, Abolfathi Momtaz Y, Hamedanchi A. Content Analysis of the Topics of Ageing-related Theses at the University of Social Welfare and Rehabilitation Sciences in Iran. Salmand: Iranian Journal of Ageing. 2018;13(3):300-11. eng. [DOI:10.32598/sija.13.3.300]
2. 2Rasel M, Ardalan A. The Future of Ageing and Its Health Care Costs: A Warning for Health System. Salmand: Iranian Journal of Ageing. 2007;2(2):300-5. eng.
3. 3Hughes R, Kleinpell M. Fletcher k. Patient safety and quality an evidence-based Hand Book for Nurses. Kleinpell M, Fletcher k, Jennings BM reducing functional decline in hospitalized elderly 9thed New York: AHRQ. 2009:251-65.
4. 4Lewis CL, Kistler CE, Amick HR, Watson LC, Bynum DL, Walter LC, et al. Older adults' attitudes about continuing cancer screening later in life: a pilot study interviewing residents of two continuing care communities. BMC Geriatr. 2006;6(1):10. [DOI:10.1186/1471-2318-6-10] [PMID] [PMCID]
5. 5Engels EA, Pfeiffer RM, Ricker W, Wheeler W, Parsons R, Warren JL. Use of surveillance, epidemiology, and end results-medicare data to conduct case-control studies of cancer among the US elderly. Am J Epidemiol. 2011;174(7):860-70. [DOI:10.1093/aje/kwr146] [PMID] [PMCID]
6. 6Sadjadi A, Nooraie M, Ghorbani A, Alimohammadian M, Zahedi M-J, Darvish-Moghadam S, et al. The incidence of prostate cancer in Iran: results of a population-based cancer registry. Arch Iran Med. 2007;10(4):481-5.
7. 7Pourmand G, Allameh F, Mohammad K, Dehghani S, Pourmand B, Mehrsai A, et al. Prostate cancer predicting factors: a preliminary report from Tehran. Urology journal. 2012;9(4):667-72.
8. 8Hassanipour S, Fathalipour M, Salehiniya H. The incidence of prostate cancer in Iran: a systematic review and meta-analysis. Prostate International. 2018;6(2):41-5. [DOI:10.1016/j.prnil.2017.11.003] [PMID] [PMCID]
9. 9Pakzad R, Rafiemanesh H, Ghoncheh M, Sarmad A, Salehiniya H, Hosseini S, et al. Prostate cancer in Iran: trends in incidence and morphological and epidemiological characteristics. Asian Pac J Cancer Prev. 2016;17(2):839-43. [DOI:10.7314/APJCP.2016.17.2.839] [PMID]
10. 10Jewett MA, Fleshner N, Klotz LH, Nam RK, Trachtenberg J. Radical prostatectomy as treatment for prostate cancer. Can Med Assoc J. 2003;168(1):44-5.
11. 11Pollack A, Zagars GK, Smith LG, Lee JJ, von Eschenbach AC, Antolak JA, et al. Preliminary results of a randomized radiotherapy dose-escalation study comparing 70 Gy with 78 Gy for prostate cancer. J Clin Oncol. 2000;18(23):3904-11. [DOI:10.1200/JCO.2000.18.23.3904] [PMID]
12. 12Damber J-E, Aus G. Prostate cancer. The Lancet. 2008;371(9625):1710-21. [DOI:10.1016/S0140-6736(08)60729-1]
13. 13Kehinde EO, Mojiminiyi OA, Sheikh M, Al‐Awadi KA, Daar AS, Al‐Hunayan A, et al. Age‐specific reference levels of serum prostate‐specific antigen and prostate volume in healthy Arab men. BJU international. 2005;96(3):308-12. [DOI:10.1111/j.1464-410X.2005.05620.x] [PMID]
14. 14Yu M, Law NJ, Taylor JM, Sandler HM. Joint longitudinal-survival-cure models and their application to prostate cancer. Statistica Sinica. 2004:835-62.
15. 15Jackson CH. Multi-state models for panel data: the msm package for R. Journal of Statistical Software. 2011;38(8):1-29. [DOI:10.18637/jss.v038.i08]
16. 16Meira-Machado L, de Uña-Álvarez J, Cadarso-Suárez C, Andersen PK. Multi-state models for the analysis of time-to-event data. Stat Methods Med Res. 2009;18(2):195-222. [DOI:10.1177/0962280208092301] [PMID] [PMCID]
17. 17Galvin A, Helmer C, Coureau G, Amadeo B, Joly P, Sabathé C, et al. Determinants of cancer treatment and mortality in older cancer patients using a multi-state model: Results from a population-based study (the INCAPAC study). Cancer Epidemiol. 2018;55:39-44. [DOI:10.1016/j.canep.2018.04.013] [PMID]
18. 18Ferrer L, Rondeau V, Dignam J, Pickles T, Jacqmin‐Gadda H, Proust‐Lima C. Joint modelling of longitudinal and multi‐state processes: application to clinical progressions in prostate cancer. Stat Med. 2016;35(22):3933-48. [DOI:10.1002/sim.6972] [PMID] [PMCID]
19. 19Beesley LJ, Morgan TM, Spratt DE, Singhal U, Feng FY, Furgal AC, et al. Individual and Population Comparisons of Surgery and Radiotherapy Outcomes in Prostate Cancer Using Bayesian Multistate Models. JAMA network open. 2019;2(2):e187765-e. [DOI:10.1001/jamanetworkopen.2018.7765] [PMID] [PMCID]

Add your comments about this article : Your username or Email:

Send email to the article author

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2021 CC BY-NC 4.0 | Iranian Journal of Ageing

Designed & Developed by : Yektaweb